Hope for stargardt patients: new drug aims to slow blindness
NCT ID NCT07419334
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an oral drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, a genetic condition that causes progressive vision loss. Participants take the drug or a placebo daily for 24 months. The goal is to see if the drug can slow the growth of retinal damage and preserve eyesight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gildeuretinol acetate (ALK 001)
What this could lead to
If it works, this could slow the progression of Stargardt disease and help preserve vision longer.
What could go wrong
This is still an experimental drug. Even in Phase 3, it may not prove effective, and side effects are possible. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Associated Retina Consultants
RECRUITINGPhoenix, Arizona, 85020, United States
Contact
Contact Email: •••••@•••••
-
Erie Retina Research
RECRUITINGErie, Pennsylvania, 16505, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vitreo Retinal Associates
NOT_YET_RECRUITINGGainesville, Florida, 32607, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••